Cystic fibrosis (CF), one of the most commonly observed and diagnosed fatal monogenic disorders globally, was initially thought to affect individuals of Caucasian/European descent almost exclusively. It is increasingly appreciated, however, that nonCaucasian populations are also affected by this condition. Although this has been known in South Africa (SA) for over two decades, a large disparity still exists in data pertaining to the different population groups in the country. This article seeks to highlight existing published data on CF in SA populations and reflects on the means through which these have been generated over the years. Additionally, the article briefly discusses the consequences of incomplete data and how this could potentially be addressed in the future through innovative and collaborative approaches.
IN PRACTICE
Cystic fibrosis (CF), one of the most commonly diagnosed mono genic disorders, has been well researched in many nations. Primarily affecting the mucussecreting organs of the body, such as the lungs, pancreas, liver and intestinal tract, no cure has been developed for this fatal disorder. Nevertheless, assisted by largescale research efforts and advances in sequencing technologies, several countries, including Australia, Belgium, Canada, France, Germany, the UK, The Netherlands and the USA, have successfully established CF registries. These registries have had a positive impact on the management and therefore on the quality of life of patients with CF and have also provided benefit in terms of reducing the costs associated with their care. [13] In countries in which CF research has been well established and where CF registries and/or newborn screening programmes exist, median survival rates for patients with CF have increased steadily year on year. Currently the median age of survival is 52 years in Canada, [4] 42 years in the USA, [5] 40 years in Europe [6] and 27 years in Australia. [7] In South Africa (SA), the life expectancy of a CF patient, as reported in 2008, was less than 21 years. [8] In comparison, life expectancy for Canadian, American, French, British and Australian CF patients in the same year was approximately 30, 37, 28, 27 and 30 years, respectively.
[913] Westwood [8] also highlighted the difference that existed between the median age of death in white individuals with CF, i.e. of Caucasian/European descent (25.8 years), and patients of mixed race (20.5 years) in the Western Cape Province of SA. Nevertheless, very little is known about causative CF variants in SA and other African nations. [14, 15] This difference is due in part to the widespread and incorrect belief that CF only affects 'white' populations -a notion that is increasingly being shown to be incorrect. [16, 17] Consequences of an age-old problem and potential solutions
The initial assumption that CF could only affect white South Africans was in part based on the observed disparity in mutation detection rates between population groups. Variations in mutation detection rates have been influenced further by the fact that many CFcausing variants are population specific. Currently, more is known about CF mutations found in the wellcharacterised white SA population than any of the other affected population groups. As a result, causative variants are typically identified in 83% of white SA CF patients, while CFassociated variants have previously only been identified in 55% and 21% of mixedrace and black SA CF patients, respectively. [18] Screening panels initially used to diagnose CF in SA patients were based on variants that are common to European populations, and while attempts have been made to collect larger numbers of CF samples in other patient groups in SA, few publications addressing the chasm in variant data exist.
A lack of CF data in nonCaucasoid population groups is common to SA and other African countries. There are no patient registries for this disease on the African continent, which means that African CF patients cannot benefit from clinical interventions planned on the basis of trends in registry data. Despite the unparalleled genomic diversity that exists in African populations, African genomes have been vastly understudied. [19] This is illustrated in patients in whom genetic testing returns falsenegative results because the CFcausing mutations have not been fully characterised in their population(s). In some cases, this problem has been resolved through the application of gene sequencing methods. [20, 21] Adding further complexity to existing information is the fact that a significant proportion of reported SA CF data were published over 10 years ago (Table 1) . Altogether, when considering the lack of data and the absence of an SA newborn screening programme, making a quick and accurate molecular diagnosis of CF is difficult in many cases, and assessing the health of the local CF population in order to propose and implement the interventions needed to improve prognosis is challenging.
Early detection of CF has repeatedly been shown to be of benefit to patients and public healthcare systems. [30, 31] For instance, in 2012, 65%, 63%, and 50% of all new CF cases in Australia, France and The Netherlands, respectively, were detected through neonatal screening
programmes.
[12, 32, 33] In 2011, neonatal screening accounted for the detection of 74% of all new CF cases in the UK. [13] This has been highly beneficial, since early detection of CF can reduce negative nutritional outcomes, general health complications and decline in cognitive capacity, thereby improving the overall health of affected patients. [34, 35] Early diagnosis has also been shown to provide an economic benefit. For example, Dutch patients identified by newborn screening programmes spend about a million euros less on treatment over the course of their lives than patients not discovered through this method. [36] Interestingly, despite the clearly demonstrated benefit of early diagnosis, in studies conducted on SA CF patients there is no correlation between specific CF variants and the severity of lung function decline and associated nutritional status. [37, 38] Based on CF variant data that are currently available, the most common CF variants in SA are ΔF508, c.3120+1G>A, c.327226A>G and 394delTT, which have been identified in 69.8%, 13.2%, 3.4%, and 3.0% of screened patients, respectively (Table 2) . However, as reflected in Table 1 , different screening methods were used in the detection of these variants. Although not always feasible, especially in early studies, it must also be noted that not a single reported study has made use of an unbiased DNA sequencing approach. For example, many black SA patients are screened only for the presence of the c.3120+1G>A variant in order to make a positive molecular diagnosis of CF. [17, 18, 39] Novel or SAspecific mutations in the major population groups have therefore gone undiscovered or could not have been detected owing to limited screening capacity. An additional confounding factor, as illustrated in Table 3 , is that SA CF data have largely been dominated by white patients, a minority genetic group in the country. Although historical factors are largely responsible for this phenomenon, access to and the cost of sequencing technology now make it possible to obtain new information with relative ease, affordability and speed. [40] Use of advanced sequencing methods, particularly in majority population groups, would be of benefit to SA CF patients, since SA is home to some of the most genetically diverse population groups in the world. [41] A need for more molecular data to assist with accurately diagnosing SA and African CF patients therefore exists. Nevertheless, as illustrated by existing CF registries, several types of data (and not just causative variant information) are investigated. In the absence of molecular data, developing algorithms that can aid in the diagnosis of CF given limited clinical, biochemical and/or molecular information may be invaluable to SA clinicians in the interim. Although such programmes/tools are only as good as the quality and quantity of available data, they at least have the potential to present baseline probabilities as to a positive CF diagnosis. Such tools might easily serve as a standard by which potential CF patients could be selected for sequencing projects, thereby maximising the odds of identifying previously undescribed CF variants. In so doing, more exact data could be fed back into diagnostic algorithms to improve their accuracy.
Conclusions
The lack of standardised SA CF data is having a negative impact on the longevity of SA CF patients. Driving CF research with the distinct aims of: (i) identifying CF variants relevant to all SA population groups; (ii) establishing and maintaining a countryspecific CF database/registry; (iii) establishing a solid foundation for a newborn screening programme; and (iv) exploring novel means through which a positive clinical diagnosis could be made (given limited molecular data) would be of great benefit to the overall care received by many local patients. The first of these points can be achieved through the use of nextgeneration sequencing methods, wholeexome sequencing, and/or targeted sequencing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Although presenting 
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their own unique challenges, sincere, multidisciplinary collaborative efforts that involve stakeholders from academic, private, public and government sectors would be able to address the remaining points. [42] Together, these changes could ensure a healthier and longer future for all SA CF patients.
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